市場調査レポート

商品コード

1447173

医薬品懸濁液市場：タイプ別、適応症別、エンドユーザー別、流通チャネル別：世界の機会分析と産業予測、2023年～2032年

Pharmaceutical Suspension Market By Type, By Indication, By End User, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2023-2032

出版日: 2024年01月30日 | 発行: Allied Market Research

| ページ情報: 英文 315 Pages | 納期: 2～3営業日

価格

Cloud Access (Single User License)

USD 3,840 601,536円

レポートのクラウドアクセスでご利用頂けるライセンスです。ウェブポータルで配信され、60日間レポートにアクセスできます。この期間を過ぎるとレポートへのアクセスは失効します。コンテンツのダウンロード、印刷、共有、コピー＆ペーストはできません。

PDF (Business License)

USD 6,090 953,998円

レポートPDFをご利用いただけるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDFl内のテキスト等のコピー＆ペーストは可能です。印刷は5回可能です。追加料金を支払うことで、2～5ユーザーを収容できるようにアップグレードできます。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 10,500 1,644,825円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.65円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

医薬品懸濁液市場は、2022年に555億米ドルと評価され、2023年から2032年にかけてCAGR 4.2%で成長し、2032年には838億米ドルに達すると推定されます。

医薬品懸濁液は、液体媒体中に固体粒子を微細に分散させた液体製剤であり、多くの場合、経口または非経口投与用です。これらの懸濁液は汎用性の高いドラッグデリバリーシステムを提供し、難溶性薬物の安定性とバイオアベイラビリティを高めることができます。一般的に難溶性の薬物である固体粒子は、液相中に均一に分散され、沈降を防止します。医薬品懸濁液は、投与が容易で、患者のコンプライアンスが向上し、投与量の調整が柔軟に行えるなどの利点を提供します。溶解度プロファイルが変化する薬剤を送達する上で重要な役割を果たし、治療効果を保証します。この製剤の適応性により、多様な病状に適した選択肢となり、製薬業界で広く使用される要因となっています。

医薬品懸濁液市場は、感染症、がん、神経疾患などの慢性疾患の有病率の上昇に起因する著しい成長を示しています。米国がん協会によると、2023年には米国だけで195万8310人の新規がん患者が発生しました。同様に、米国国立衛生研究所によると、世界全体の40％以上の人々が胃腸合併症に苦しんでいます。このような疾病の急増は、効果的なドラッグ・デリバリー・システムの必要性を強調しています。医薬品懸濁液は、薬剤投与のための汎用性の高いプラットフォームを提供し、市場で極めて重要な役割を果たしています。

このような慢性疾患が蔓延するにつれて、医薬品懸濁液市場は、このような健康課題に関連する複雑な治療要件に対処する必要性によって、拡大する態勢を整えています。しかし、安定性や溶解性の問題から、すべての薬剤が懸濁液を通じて効果的に送達されるわけではないため、薬剤の適合性には限界があり、市場成長の妨げとなっています。さらに、特殊な装置や工程を必要とするなど製造が複雑なため、製造コストが上昇し、製造業者の数が制限されるため、市場へのアクセスや購入しやすさが制限されます。

医薬品懸濁液市場は、タイプ、適応症、エンドユーザー、流通チャネル、地域に区分されます。タイプ別では、市場は経口剤、非経口剤、その他に区分されます。適応症別では、感染症、がん、消化器、神経、その他に区分されます。エンドユーザー別では、市場は病院・診療所、在宅医療現場、その他に区分されます。流通チャネル別では、市場は病院薬局、ドラッグストア・小売薬局、オンラインプロバイダーに区分されます。地域別では、市場は北米、欧州、アジア太平洋、LAMEAで分析されます。

利害関係者にとっての主なメリット

当レポートは、2022年から2032年までの医薬品懸濁液市場分析の市場セグメント、現在の動向、推定・動向分析、力学の定量分析を提供し、一般的な医薬品懸濁液市場機会を特定します。
市場促進要因、市場抑制要因、市場機会に関連する情報とともに市場調査を提供します。
ポーターのファイブフォース分析では、利害関係者が利益重視のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるように、バイヤーとサプライヤーの潜在力を強調します。
医薬品懸濁液市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
各地域の主要国は、世界市場への収益貢献度に応じてマッピングされています。
市場プレイヤーのポジショニングはベンチマークを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
地域別および世界の医薬品懸濁液の市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析も含まれています。

本レポートで可能なカスタマイズ（追加費用とスケジュールが必要です。）

技術動向分析
国、地域、世界レベルでの患者/疫学データ
規制ガイドライン
クライアントの関心に特化した追加企業プロファイル
企業プロファイルの拡張リスト
過去の市場データ
SWOT分析

市場の定義と範囲
主な調査結果
- 影響要因
- 主な投資機会
ポーターのファイブフォース分析
市場力学
- 促進要因
  - 医薬品開発活動の増加
  - 懸濁製剤がもたらす患者のコンプライアンス
  - ジェネリック医薬品の入手可能性
- 抑制要因
  - 薬物適合性の制限
- 機会
  - 市場拡大のためのイニシアチブの高まり

第4章医薬品懸濁液市場：タイプ別

概要
経口剤
非経口剤
その他

第5章医薬品懸濁液市場：適応症別

概要
感染症
がん
消化器
神経
その他

第6章医薬品懸濁液市場：エンドユーザー別

概要
病院および診療所
在宅医療
その他

第7章医薬品懸濁液市場：流通チャネル別

概要
病院薬局
ドラッグストアおよび小売薬局
オンラインプロバイダー

第8章医薬品懸濁液市場：地域別

概要
北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- その他
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- 韓国
- その他
ラテンアメリカ・中東・アフリカ
- ブラジル
- サウジアラビア
- 南アフリカ
- その他

第9章競争情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合ヒートマップ
主要企業のポジショニング、2022年

第10章企業プロファイル

Pfizer Inc.
Merck & Co., Inc.
AstraZeneca plc
Eli Lilly and Company.
Bayer AG
Sanofi
Lupin
Glenmark Pharmaceuticals Limited
Novartis AG
Teva Pharmaceutical Industries Limited

図表

LIST OF TABLES

TABLE 01. GLOBAL PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 02. PHARMACEUTICAL SUSPENSION MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
TABLE 03. PHARMACEUTICAL SUSPENSION MARKET FOR PARENTERAL, BY REGION, 2022-2032 ($MILLION)
TABLE 04. PHARMACEUTICAL SUSPENSION MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 06. PHARMACEUTICAL SUSPENSION MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2032 ($MILLION)
TABLE 07. PHARMACEUTICAL SUSPENSION MARKET FOR CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 08. PHARMACEUTICAL SUSPENSION MARKET FOR GASTROINTESTINAL, BY REGION, 2022-2032 ($MILLION)
TABLE 09. PHARMACEUTICAL SUSPENSION MARKET FOR NEUROLOGICAL, BY REGION, 2022-2032 ($MILLION)
TABLE 10. PHARMACEUTICAL SUSPENSION MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 11. GLOBAL PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 12. PHARMACEUTICAL SUSPENSION MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2022-2032 ($MILLION)
TABLE 13. PHARMACEUTICAL SUSPENSION MARKET FOR HOME CARE SETTINGS, BY REGION, 2022-2032 ($MILLION)
TABLE 14. PHARMACEUTICAL SUSPENSION MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 15. GLOBAL PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 16. PHARMACEUTICAL SUSPENSION MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 17. PHARMACEUTICAL SUSPENSION MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 18. PHARMACEUTICAL SUSPENSION MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
TABLE 19. PHARMACEUTICAL SUSPENSION MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 20. NORTH AMERICA PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 21. NORTH AMERICA PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 22. NORTH AMERICA PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 23. NORTH AMERICA PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 24. NORTH AMERICA PHARMACEUTICAL SUSPENSION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 25. U.S. PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 26. U.S. PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 27. U.S. PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 28. U.S. PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 29. CANADA PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 30. CANADA PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 31. CANADA PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 32. CANADA PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 33. MEXICO PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 34. MEXICO PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 35. MEXICO PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 36. MEXICO PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 37. EUROPE PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 38. EUROPE PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 39. EUROPE PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 40. EUROPE PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 41. EUROPE PHARMACEUTICAL SUSPENSION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 42. GERMANY PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 43. GERMANY PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 44. GERMANY PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 45. GERMANY PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 46. FRANCE PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 47. FRANCE PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 48. FRANCE PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 49. FRANCE PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 50. UK PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 51. UK PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 52. UK PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 53. UK PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 54. ITALY PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 55. ITALY PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 56. ITALY PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 57. ITALY PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 58. SPAIN PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 59. SPAIN PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 60. SPAIN PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 61. SPAIN PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 62. REST OF EUROPE PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 63. REST OF EUROPE PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 64. REST OF EUROPE PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 65. REST OF EUROPE PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 66. ASIA-PACIFIC PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 67. ASIA-PACIFIC PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 68. ASIA-PACIFIC PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 69. ASIA-PACIFIC PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 70. ASIA-PACIFIC PHARMACEUTICAL SUSPENSION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 71. JAPAN PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 72. JAPAN PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 73. JAPAN PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 74. JAPAN PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 75. CHINA PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 76. CHINA PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 77. CHINA PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 78. CHINA PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 79. INDIA PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 80. INDIA PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 81. INDIA PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 82. INDIA PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 83. AUSTRALIA PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 84. AUSTRALIA PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 85. AUSTRALIA PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 86. AUSTRALIA PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 87. SOUTH KOREA PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 88. SOUTH KOREA PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 89. SOUTH KOREA PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 90. SOUTH KOREA PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 91. REST OF ASIA-PACIFIC PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 92. REST OF ASIA-PACIFIC PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 93. REST OF ASIA-PACIFIC PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 94. REST OF ASIA-PACIFIC PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 95. LAMEA PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 96. LAMEA PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 97. LAMEA PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 98. LAMEA PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 99. LAMEA PHARMACEUTICAL SUSPENSION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 100. BRAZIL PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 101. BRAZIL PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 102. BRAZIL PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 103. BRAZIL PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 104. SAUDI ARABIA PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 105. SAUDI ARABIA PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 106. SAUDI ARABIA PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 107. SAUDI ARABIA PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 108. SOUTH AFRICA PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 109. SOUTH AFRICA PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 110. SOUTH AFRICA PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 111. SOUTH AFRICA PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 112. REST OF LAMEA PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 113. REST OF LAMEA PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 114. REST OF LAMEA PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 115. REST OF LAMEA PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 116. PFIZER INC.: KEY EXECUTIVES
TABLE 117. PFIZER INC.: COMPANY SNAPSHOT
TABLE 118. PFIZER INC.: PRODUCT SEGMENTS
TABLE 119. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 120. MERCK & CO., INC.: KEY EXECUTIVES
TABLE 121. MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 122. MERCK & CO., INC.: PRODUCT SEGMENTS
TABLE 123. MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 124. MERCK & CO., INC.: KEY STRATERGIES
TABLE 125. ASTRAZENECA PLC: KEY EXECUTIVES
TABLE 126. ASTRAZENECA PLC: COMPANY SNAPSHOT
TABLE 127. ASTRAZENECA PLC: PRODUCT SEGMENTS
TABLE 128. ASTRAZENECA PLC: PRODUCT PORTFOLIO
TABLE 129. ELI LILLY AND COMPANY.: KEY EXECUTIVES
TABLE 130. ELI LILLY AND COMPANY.: COMPANY SNAPSHOT
TABLE 131. ELI LILLY AND COMPANY.: PRODUCT SEGMENTS
TABLE 132. ELI LILLY AND COMPANY.: PRODUCT PORTFOLIO
TABLE 133. BAYER AG: KEY EXECUTIVES
TABLE 134. BAYER AG: COMPANY SNAPSHOT
TABLE 135. BAYER AG: PRODUCT SEGMENTS
TABLE 136. BAYER AG: PRODUCT PORTFOLIO
TABLE 137. SANOFI: KEY EXECUTIVES
TABLE 138. SANOFI: COMPANY SNAPSHOT
TABLE 139. SANOFI: PRODUCT SEGMENTS
TABLE 140. SANOFI: PRODUCT PORTFOLIO
TABLE 141. LUPIN: KEY EXECUTIVES
TABLE 142. LUPIN: COMPANY SNAPSHOT
TABLE 143. LUPIN: PRODUCT SEGMENTS
TABLE 144. LUPIN: PRODUCT PORTFOLIO
TABLE 145. LUPIN: KEY STRATERGIES
TABLE 146. GLENMARK PHARMACEUTICALS LIMITED: KEY EXECUTIVES
TABLE 147. GLENMARK PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
TABLE 148. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS
TABLE 149. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
TABLE 150. GLENMARK PHARMACEUTICALS LIMITED: KEY STRATERGIES
TABLE 151. NOVARTIS AG: KEY EXECUTIVES
TABLE 152. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 153. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 154. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 155. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
TABLE 156. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
TABLE 157. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
TABLE 158. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
TABLE 159. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES

LIST OF FIGURES

FIGURE 01. PHARMACEUTICAL SUSPENSION MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF PHARMACEUTICAL SUSPENSION MARKET,2022-2032
FIGURE 03. TOP IMPACTING FACTORS IN PHARMACEUTICAL SUSPENSION MARKET (2022 TO 2032)
FIGURE 04. TOP INVESTMENT POCKETS IN PHARMACEUTICAL SUSPENSION MARKET (2023-2032)
FIGURE 05. HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
FIGURE 07. HIGH THREAT OF SUBSTITUTES
FIGURE 08. MODERATE INTENSITY OF RIVALRY
FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
FIGURE 10. GLOBAL PHARMACEUTICAL SUSPENSION MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR ORAL, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR PARENTERAL, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR INFECTIOUS DISEASES, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR CANCER, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR GASTROINTESTINAL, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR NEUROLOGICAL, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022 AND 2032(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY 2022 AND 2032(%)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR HOME CARE SETTINGS, BY COUNTRY 2022 AND 2032(%)
FIGURE 24. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 25. PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)
FIGURE 26. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 27. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 28. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 29. PHARMACEUTICAL SUSPENSION MARKET BY REGION, 2022 AND 2032(%)
FIGURE 30. U.S. PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
FIGURE 31. CANADA PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
FIGURE 32. MEXICO PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
FIGURE 33. GERMANY PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
FIGURE 34. FRANCE PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
FIGURE 35. UK PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
FIGURE 36. ITALY PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
FIGURE 37. SPAIN PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
FIGURE 38. REST OF EUROPE PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
FIGURE 39. JAPAN PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
FIGURE 40. CHINA PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
FIGURE 41. INDIA PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
FIGURE 42. AUSTRALIA PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
FIGURE 43. SOUTH KOREA PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
FIGURE 44. REST OF ASIA-PACIFIC PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
FIGURE 45. BRAZIL PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
FIGURE 46. SAUDI ARABIA PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
FIGURE 47. SOUTH AFRICA PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
FIGURE 48. REST OF LAMEA PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
FIGURE 49. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
FIGURE 50. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
FIGURE 51. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
FIGURE 52. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 53. COMPETITIVE DASHBOARD
FIGURE 54. COMPETITIVE HEATMAP: PHARMACEUTICAL SUSPENSION MARKET
FIGURE 55. TOP PLAYER POSITIONING, 2022
FIGURE 56. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 57. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 58. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 59. MERCK & CO., INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 60. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 61. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 62. ASTRAZENECA PLC: NET SALES, 2020-2022 ($MILLION)
FIGURE 63. ASTRAZENECA PLC: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 64. ELI LILLY AND COMPANY: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 65. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 66. BAYER AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 67. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 68. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 69. SANOFI: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 70. SANOFI: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 71. SANOFI: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 72. LUPIN: NET SALES, 2020-2022 ($MILLION)
FIGURE 73. LUPIN: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 74. GLENMARK PHARMACEUTICALS LIMITED: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 75. GLENMARK PHARMACEUTICALS LIMITED: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 76. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 77. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 78. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 79. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 80. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)

Product Code: A12351

The The pharmaceutical suspension market was valued at $55.5 billion in 2022, and is estimated to reach $83.8 billion by 2032, growing at a CAGR of 4.2% from 2023 to 2032.

Pharmaceutical suspensions are liquid formulations comprising finely dispersed solid particles in a liquid medium, often for oral or parenteral administration. These suspensions provide a versatile drug delivery system allowing for enhanced stability and bioavailability of poorly soluble drugs. The solid particles, typically insoluble drugs, are uniformly dispersed in the liquid phase, preventing settling. Pharmaceutical suspensions offer advantages such as ease of administration, improved patient compliance, and flexibility in dosage adjustments. They play a crucial role in delivering drugs with variable solubility profiles, ensuring therapeutic efficacy. The formulation's adaptability makes it a preferred choice for diverse medical conditions, contributing to its widespread use in the pharmaceutical industry.

The pharmaceutical suspensions market is witnessing significant growth, attributed to rise in prevalence of chronic conditions such as infectious diseases, cancer, and neurological disorders. According to the American Cancer Society, in 2023, the U.S. alone accounted for 1,958,310 new cancer cases. Similarly, according to the National Institutes of Health, more than 40% of people globally suffer from gastrointestinal complications. This surge in disease incidence emphasizes the critical need for effective drug delivery systems. Pharmaceutical suspensions play a pivotal role in the market, offering a versatile platform for administering medications.

As these chronic conditions become more pervasive, the pharmaceutical suspensions market is poised for expansion, driven by the imperative to address the complex treatment requirements associated with such health challenges. However, limited drug compatibility hinders the market growth as not all medications are effectively delivered through suspensions due to stability and solubility issues. In addition, manufacturing complexities such as requiring specialized equipment and processes, increase production costs and restrict the number of manufacturers, limiting market accessibility and affordability.

The pharmaceutical suspension market is segmented into type, indication, end user, distribution channel, and region. On the basis of type, the market is segmented into oral, parenteral, and others. On the basis of indication, it is segmented into infectious diseases, cancer, gastrointestinal, neurological, and others. On the basis of end user, the market is segmented into hospitals and clinics, home care settings, and others. On the basis of distribution channel, the market is segmented into hospital pharmacies, drug store and retail pharmacies, and online providers. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major players that operate in the pharmaceutical suspension market include Pfizer Inc., Merck & Co., Inc., AstraZeneca plc, Eli Lilly and Company, Bayer AG, Sanofi, Lupin, Glenmark Pharmaceuticals Limited, Novartis AG, and Teva Pharmaceutical Industries Limited. The key players have adopted key strategies such as product approval and collaboration to expand their product portfolio.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pharmaceutical suspension market analysis from 2022 to 2032 to identify the prevailing pharmaceutical suspension market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the pharmaceutical suspension market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global pharmaceutical suspension market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Technology Trend Analysis
Patient/epidemiology data at country, region, global level
Regulatory Guidelines
Additional company profiles with specific to client's interest
Expanded list for Company Profiles
Historic market data
SWOT Analysis

Key Market Segments

By Type

Oral
Parenteral
Others

By Indication

Infectious Diseases
Cancer
Gastrointestinal
Neurological
Others

By End User

Hospitals and Clinics
Home Care Settings
Others

By Distribution Channel

Hospital Pharmacies
Drug Store and Retail Pharmacies
Online Providers

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Pfizer Inc.
AstraZeneca plc
Eli Lilly and Company.
Sanofi
Lupin
Novartis AG
Teva Pharmaceutical Industries Limited
Merck & Co., Inc.
Bayer AG
Glenmark Pharmaceuticals Limited

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. High bargaining power of suppliers
- 3.3.2. Moderate threat of new entrants
- 3.3.3. High threat of substitutes
- 3.3.4. Moderate intensity of rivalry
- 3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Increased Drug Development Activities
  - 3.4.1.2. Patient Compliance offered by pharmaceutical suspensions
  - 3.4.1.3. Availability of generic pharmaceutical suspensions
- 3.4.2. Restraints
  - 3.4.2.1. Limited drug compatibility
- 3.4.3. Opportunities
  - 3.4.3.1. Growing initiatives for market expansion

CHAPTER 4: PHARMACEUTICAL SUSPENSION MARKET, BY TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Oral
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Parenteral
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Others
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country

CHAPTER 5: PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Infectious Diseases
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Cancer
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Gastrointestinal
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
5.5. Neurological
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country
5.6. Others
- 5.6.1. Key market trends, growth factors and opportunities
- 5.6.2. Market size and forecast, by region
- 5.6.3. Market share analysis by country

CHAPTER 6: PHARMACEUTICAL SUSPENSION MARKET, BY END USER

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospitals and Clinics
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Home Care Settings
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Others
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL

7.1. Overview
- 7.1.1. Market size and forecast
7.2. Hospital Pharmacies
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by region
- 7.2.3. Market share analysis by country
7.3. Drug Store and Retail Pharmacies
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by region
- 7.3.3. Market share analysis by country
7.4. Online Providers
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by region
- 7.4.3. Market share analysis by country

CHAPTER 8: PHARMACEUTICAL SUSPENSION MARKET, BY REGION

8.1. Overview
- 8.1.1. Market size and forecast By Region
8.2. North America
- 8.2.1. Key market trends, growth factors and opportunities
- 8.2.2. Market size and forecast, by Type
- 8.2.3. Market size and forecast, by Indication
- 8.2.4. Market size and forecast, by End User
- 8.2.5. Market size and forecast, by Distribution Channel
- 8.2.6. Market size and forecast, by country
  - 8.2.6.1. U.S.
  - 8.2.6.1.1. Market size and forecast, by Type
  - 8.2.6.1.2. Market size and forecast, by Indication
  - 8.2.6.1.3. Market size and forecast, by End User
  - 8.2.6.1.4. Market size and forecast, by Distribution Channel
  - 8.2.6.2. Canada
  - 8.2.6.2.1. Market size and forecast, by Type
  - 8.2.6.2.2. Market size and forecast, by Indication
  - 8.2.6.2.3. Market size and forecast, by End User
  - 8.2.6.2.4. Market size and forecast, by Distribution Channel
  - 8.2.6.3. Mexico
  - 8.2.6.3.1. Market size and forecast, by Type
  - 8.2.6.3.2. Market size and forecast, by Indication
  - 8.2.6.3.3. Market size and forecast, by End User
  - 8.2.6.3.4. Market size and forecast, by Distribution Channel
8.3. Europe
- 8.3.1. Key market trends, growth factors and opportunities
- 8.3.2. Market size and forecast, by Type
- 8.3.3. Market size and forecast, by Indication
- 8.3.4. Market size and forecast, by End User
- 8.3.5. Market size and forecast, by Distribution Channel
- 8.3.6. Market size and forecast, by country
  - 8.3.6.1. Germany
  - 8.3.6.1.1. Market size and forecast, by Type
  - 8.3.6.1.2. Market size and forecast, by Indication
  - 8.3.6.1.3. Market size and forecast, by End User
  - 8.3.6.1.4. Market size and forecast, by Distribution Channel
  - 8.3.6.2. France
  - 8.3.6.2.1. Market size and forecast, by Type
  - 8.3.6.2.2. Market size and forecast, by Indication
  - 8.3.6.2.3. Market size and forecast, by End User
  - 8.3.6.2.4. Market size and forecast, by Distribution Channel
  - 8.3.6.3. UK
  - 8.3.6.3.1. Market size and forecast, by Type
  - 8.3.6.3.2. Market size and forecast, by Indication
  - 8.3.6.3.3. Market size and forecast, by End User
  - 8.3.6.3.4. Market size and forecast, by Distribution Channel
  - 8.3.6.4. Italy
  - 8.3.6.4.1. Market size and forecast, by Type
  - 8.3.6.4.2. Market size and forecast, by Indication
  - 8.3.6.4.3. Market size and forecast, by End User
  - 8.3.6.4.4. Market size and forecast, by Distribution Channel
  - 8.3.6.5. Spain
  - 8.3.6.5.1. Market size and forecast, by Type
  - 8.3.6.5.2. Market size and forecast, by Indication
  - 8.3.6.5.3. Market size and forecast, by End User
  - 8.3.6.5.4. Market size and forecast, by Distribution Channel
  - 8.3.6.6. Rest of Europe
  - 8.3.6.6.1. Market size and forecast, by Type
  - 8.3.6.6.2. Market size and forecast, by Indication
  - 8.3.6.6.3. Market size and forecast, by End User
  - 8.3.6.6.4. Market size and forecast, by Distribution Channel
8.4. Asia-Pacific
- 8.4.1. Key market trends, growth factors and opportunities
- 8.4.2. Market size and forecast, by Type
- 8.4.3. Market size and forecast, by Indication
- 8.4.4. Market size and forecast, by End User
- 8.4.5. Market size and forecast, by Distribution Channel
- 8.4.6. Market size and forecast, by country
  - 8.4.6.1. Japan
  - 8.4.6.1.1. Market size and forecast, by Type
  - 8.4.6.1.2. Market size and forecast, by Indication
  - 8.4.6.1.3. Market size and forecast, by End User
  - 8.4.6.1.4. Market size and forecast, by Distribution Channel
  - 8.4.6.2. China
  - 8.4.6.2.1. Market size and forecast, by Type
  - 8.4.6.2.2. Market size and forecast, by Indication
  - 8.4.6.2.3. Market size and forecast, by End User
  - 8.4.6.2.4. Market size and forecast, by Distribution Channel
  - 8.4.6.3. India
  - 8.4.6.3.1. Market size and forecast, by Type
  - 8.4.6.3.2. Market size and forecast, by Indication
  - 8.4.6.3.3. Market size and forecast, by End User
  - 8.4.6.3.4. Market size and forecast, by Distribution Channel
  - 8.4.6.4. Australia
  - 8.4.6.4.1. Market size and forecast, by Type
  - 8.4.6.4.2. Market size and forecast, by Indication
  - 8.4.6.4.3. Market size and forecast, by End User
  - 8.4.6.4.4. Market size and forecast, by Distribution Channel
  - 8.4.6.5. South Korea
  - 8.4.6.5.1. Market size and forecast, by Type
  - 8.4.6.5.2. Market size and forecast, by Indication
  - 8.4.6.5.3. Market size and forecast, by End User
  - 8.4.6.5.4. Market size and forecast, by Distribution Channel
  - 8.4.6.6. Rest of Asia-Pacific
  - 8.4.6.6.1. Market size and forecast, by Type
  - 8.4.6.6.2. Market size and forecast, by Indication
  - 8.4.6.6.3. Market size and forecast, by End User
  - 8.4.6.6.4. Market size and forecast, by Distribution Channel
8.5. LAMEA
- 8.5.1. Key market trends, growth factors and opportunities
- 8.5.2. Market size and forecast, by Type
- 8.5.3. Market size and forecast, by Indication
- 8.5.4. Market size and forecast, by End User
- 8.5.5. Market size and forecast, by Distribution Channel
- 8.5.6. Market size and forecast, by country
  - 8.5.6.1. Brazil
  - 8.5.6.1.1. Market size and forecast, by Type
  - 8.5.6.1.2. Market size and forecast, by Indication
  - 8.5.6.1.3. Market size and forecast, by End User
  - 8.5.6.1.4. Market size and forecast, by Distribution Channel
  - 8.5.6.2. Saudi Arabia
  - 8.5.6.2.1. Market size and forecast, by Type
  - 8.5.6.2.2. Market size and forecast, by Indication
  - 8.5.6.2.3. Market size and forecast, by End User
  - 8.5.6.2.4. Market size and forecast, by Distribution Channel
  - 8.5.6.3. South Africa
  - 8.5.6.3.1. Market size and forecast, by Type
  - 8.5.6.3.2. Market size and forecast, by Indication
  - 8.5.6.3.3. Market size and forecast, by End User
  - 8.5.6.3.4. Market size and forecast, by Distribution Channel
  - 8.5.6.4. Rest of LAMEA
  - 8.5.6.4.1. Market size and forecast, by Type
  - 8.5.6.4.2. Market size and forecast, by Indication
  - 8.5.6.4.3. Market size and forecast, by End User
  - 8.5.6.4.4. Market size and forecast, by Distribution Channel

CHAPTER 9: COMPETITIVE LANDSCAPE

9.1. Introduction
9.2. Top winning strategies
9.3. Product mapping of top 10 player
9.4. Competitive dashboard
9.5. Competitive heatmap
9.6. Top player positioning, 2022

CHAPTER 10: COMPANY PROFILES

10.1. Pfizer Inc.
- 10.1.1. Company overview
- 10.1.2. Key executives
- 10.1.3. Company snapshot
- 10.1.4. Operating business segments
- 10.1.5. Product portfolio
- 10.1.6. Business performance
10.2. Merck & Co., Inc.
- 10.2.1. Company overview
- 10.2.2. Key executives
- 10.2.3. Company snapshot
- 10.2.4. Operating business segments
- 10.2.5. Product portfolio
- 10.2.6. Business performance
- 10.2.7. Key strategic moves and developments
10.3. AstraZeneca plc
- 10.3.1. Company overview
- 10.3.2. Key executives
- 10.3.3. Company snapshot
- 10.3.4. Operating business segments
- 10.3.5. Product portfolio
- 10.3.6. Business performance
10.4. Eli Lilly and Company.
- 10.4.1. Company overview
- 10.4.2. Key executives
- 10.4.3. Company snapshot
- 10.4.4. Operating business segments
- 10.4.5. Product portfolio
- 10.4.6. Business performance
10.5. Bayer AG
- 10.5.1. Company overview
- 10.5.2. Key executives
- 10.5.3. Company snapshot
- 10.5.4. Operating business segments
- 10.5.5. Product portfolio
- 10.5.6. Business performance
10.6. Sanofi
- 10.6.1. Company overview
- 10.6.2. Key executives
- 10.6.3. Company snapshot
- 10.6.4. Operating business segments
- 10.6.5. Product portfolio
- 10.6.6. Business performance
10.7. Lupin
- 10.7.1. Company overview
- 10.7.2. Key executives
- 10.7.3. Company snapshot
- 10.7.4. Operating business segments
- 10.7.5. Product portfolio
- 10.7.6. Business performance
- 10.7.7. Key strategic moves and developments
10.8. Glenmark Pharmaceuticals Limited
- 10.8.1. Company overview
- 10.8.2. Key executives
- 10.8.3. Company snapshot
- 10.8.4. Operating business segments
- 10.8.5. Product portfolio
- 10.8.6. Business performance
- 10.8.7. Key strategic moves and developments
10.9. Novartis AG
- 10.9.1. Company overview
- 10.9.2. Key executives
- 10.9.3. Company snapshot
- 10.9.4. Operating business segments
- 10.9.5. Product portfolio
- 10.9.6. Business performance
10.10. Teva Pharmaceutical Industries Limited
- 10.10.1. Company overview
- 10.10.2. Key executives
- 10.10.3. Company snapshot
- 10.10.4. Operating business segments
- 10.10.5. Product portfolio
- 10.10.6. Business performance
- 10.10.7. Key strategic moves and developments

医薬品懸濁液市場：タイプ別、適応症別、エンドユーザー別、流通チャネル別：世界の機会分析と産業予測、2023年～2032年

Pharmaceutical Suspension Market By Type, By Indication, By End User, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2023-2032

利害関係者にとっての主なメリット

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章医薬品懸濁液市場：タイプ別

第5章医薬品懸濁液市場：適応症別

第6章医薬品懸濁液市場：エンドユーザー別

第7章医薬品懸濁液市場：流通チャネル別

第8章医薬品懸濁液市場：地域別

第9章競争情勢

第10章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Type

By Indication

By End User

By Distribution Channel

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: PHARMACEUTICAL SUSPENSION MARKET, BY TYPE

CHAPTER 5: PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION

CHAPTER 6: PHARMACEUTICAL SUSPENSION MARKET, BY END USER

CHAPTER 7: PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 8: PHARMACEUTICAL SUSPENSION MARKET, BY REGION

CHAPTER 9: COMPETITIVE LANDSCAPE

CHAPTER 10: COMPANY PROFILES

医薬品懸濁液市場：タイプ別、適応症別、エンドユーザー別、流通チャネル別：世界の機会分析と産業予測、2023年～2032年

Pharmaceutical Suspension Market By Type, By Indication, By End User, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2023-2032

利害関係者にとっての主なメリット

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

第4章 医薬品懸濁液市場：タイプ別

第5章 医薬品懸濁液市場：適応症別

第6章 医薬品懸濁液市場：エンドユーザー別

第7章 医薬品懸濁液市場：流通チャネル別

第8章 医薬品懸濁液市場：地域別

第9章 競争情勢

第10章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Type

By Indication

By End User

By Distribution Channel

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: PHARMACEUTICAL SUSPENSION MARKET, BY TYPE

CHAPTER 5: PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION

CHAPTER 6: PHARMACEUTICAL SUSPENSION MARKET, BY END USER

CHAPTER 7: PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 8: PHARMACEUTICAL SUSPENSION MARKET, BY REGION

CHAPTER 9: COMPETITIVE LANDSCAPE

CHAPTER 10: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章医薬品懸濁液市場：タイプ別

第5章医薬品懸濁液市場：適応症別

第6章医薬品懸濁液市場：エンドユーザー別

第7章医薬品懸濁液市場：流通チャネル別

第8章医薬品懸濁液市場：地域別

第9章競争情勢

第10章企業プロファイル